Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENLIE Pharmaceutical JSCHSTC:BCP 25 Equity-to-Asset is 0.00 as of . 20. GuruFocus rates HSTC:BCP with a GF Score™ of 25/100. Among 1,006 Drug Manufacturers companies, ENLIE Pharmaceutical JSC ranks worse than 99403.48% on this metric.
The historical rank and industry rank for ENLIE Pharmaceutical JSC's Equity-to-Asset or its related term are showing as below:
HSTC:BCP's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.61 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
ENLIE Pharmaceutical JSC Equity-to-Asset Related Terms
ENLIE Pharmaceutical JSC Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENLIE Pharmaceutical JSC Equity-to-Asset Chart
ENLIE Pharmaceutical JSC Annual Data
Trend
Equity-to-Asset
ENLIE Pharmaceutical JSC Semi-Annual Data
Equity-to-Asset
HSTC:BCP vs : Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ENLIE Pharmaceutical JSC's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENLIE Pharmaceutical JSC Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ENLIE Pharmaceutical JSC's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where ENLIE Pharmaceutical JSC's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
ENLIE Pharmaceutical JSC's Equity to Asset Ratio for the fiscal year that ended in . 20 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENLIE Pharmaceutical JSC (HSTC:BCP) has a Equity-to-Asset of 0.00 as of . 20. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ENLIE Pharmaceutical JSC and its competitors. According to the industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 1006 companies in the Drug Manufacturers industry.
Is ENLIE Pharmaceutical JSC's Equity-to-Asset too high?
ENLIE Pharmaceutical JSC's current Equity-to-Asset is 0.00. Based on the distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ENLIE Pharmaceutical JSC has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENLIE Pharmaceutical JSC's Equity-to-Asset compare to ?
According to the Drug Manufacturers industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 1006 companies for Equity-to-Asset. This places ENLIE Pharmaceutical JSC in the lower half of its industry. The industry median Equity-to-Asset is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ENLIE Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENLIE Pharmaceutical JSC's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENLIE Pharmaceutical JSC stock overvalued right now?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. ENLIE Pharmaceutical JSC's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For ENLIE Pharmaceutical JSC (HSTC:BCP), the current Equity-to-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENLIE Pharmaceutical JSC is engaged in the production and trading of pharmaceuticals, medical supplies, cosmetics, foods, and functional foods. It is also engaged in the wholesale of other installation materials and equipment in the construction.
25GF Score
Get the complete analysis for HSTC:BCP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:BCP has been successfully added to your 
